Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for discovery and development, announced that The Dow Chemical Company (NYSE: DOW) has licensed both its best-in-class GastroPlus™ and ADMET Predictor™ software programs.
John DiBella, vice president of marketing and sales for Simulations Plus, said, “Dow again demonstrates its foresight by incorporating our modeling and simulation technology to assist with their toxicology and environmental research activities. There is an appreciation for how the tight integration of our Quantitative Structure-Activity Relationship (QSAR) and Physiologically-Based Pharmacokinetic (PBPK) modeling tools streamline the process of generating in vivo simulation results through different administration routes. We look forward to working with Dow scientists in these areas and identifying potential areas for collaboration. This announcement, following closely on the news that the U.S. EPA has added licenses of our software, provides further evidence that our programs have applications across several industries.”